查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1387488

癌症单株抗体市场报告：2030 年趋势、预测与竞争分析

Cancer Monoclonal Antibodies Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

癌症单株抗体的趋势和预测

2030年，全球癌症单株抗体市场预计将达到1,537亿美元，2024年至2030年的复合年增长率为12.4%。该市场的主要驱动因素是研发活动投资的增加、个人化医疗的增加以及全球癌症发生率的增加。全球癌症单株抗体市场的未来充满希望，医院和研究机构市场充满机会。

癌症单株抗体市场洞察

Lucintel 预测，由于小鼠单株抗体的可负担性、可用性和生产时间短，预计人源化抗体将在预测期内达到最高成长。

由于癌症盛行率不断上升和住院患者数量不断增加，医院将继续成为该市场的最大细分市场。

由于对先进治疗的认识不断增强、癌症患病率上升以及该地区主要市场参与企业的存在，预计北美在预测期内仍将是最大的地区。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2. 未来哪个细分市场成长较快？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和业务风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去五年发生了哪些併购事件，对产业产生了哪些影响？

目录

第一章执行摘要

第二章全球癌症单株抗体市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球癌症单株抗体市场趋势（2018-2023）与预测（2024-2030）
  • 按类型分類的全球癌症单株抗体市场
    • 人性化
    • 人类
    • 嵌合体
    • 小鼠或大鼠
  • 全球癌症单株抗体市场（按应用）
    • 血癌
    • 乳癌
    • 肺癌
    • 黑色素瘤
    • 大肠直肠癌
    • 肝癌
    • 其他的
  • 全球癌症单株抗体市场（依最终用途）
    • 医院
    • 研究机构
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球癌症单株抗体市场（按地区）
  • 北美癌症单株抗体市场
  • 欧洲癌症单株抗体市场
  • 亚太地区癌症单株抗体市场
  • 其他地区癌症单株抗体市场

第五章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按类型分類的全球癌症单株抗体市场成长机会
    • 全球癌症单株抗体市场成长机会（按应用）
    • 全球癌症单株抗体市场成长机会（依最终用途）
    • 全球癌症单株抗体市场成长机会（按地区）
  • 全球癌症单株抗体市场新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球癌症单株抗体市场的产能
    • 全球癌症单株抗体市场的合併、收购和合资企业
    • 认证和许可

第七章主要企业概况

  • F. Hoffmann-La Roche
  • Bristol Myers Squibb
  • Merck
  • GlaxoSmithKline
  • Johnson & Johnson
  • Amgen
  • Novartis
  • AstraZeneca
  • Eli Lilly
  • AbbVie
简介目录

Cancer Monoclonal Antibodies Trends and Forecast

The future of the global cancer monoclonal antibodies market looks promising with opportunities in the hospital and research institute markets. The global cancer monoclonal antibodies market is expected to reach an estimated $153.7 billion by 2030 with a CAGR of 12.4% from 2024 to 2030. The major drivers for this market are increasing investment in research and development activities, rising inclination towards personalized medicines, and growing prevalance of cancer across the globe.

A more than 150-page report is developed to help in your business decisions.

Cancer Monoclonal Antibodies by Segment

The study includes a forecast for the global cancer monoclonal antibodies by type, application, end use, and region.

Cancer Monoclonal Antibodies Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Humanized
  • Human
  • Chimeric
  • Murine

Cancer Monoclonal Antibodies Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Blood Cancer
  • Breast Cancer
  • Lung Cancer
  • Melanoma
  • Colorectal Cancer
  • Liver Cancer
  • Others

Cancer Monoclonal Antibodies Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Research Institutes
  • Others

Cancer Monoclonal Antibodies Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Cancer Monoclonal Antibodies Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer monoclonal antibodies companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer monoclonal antibodies companies profiled in this report include-

  • F. Hoffmann-La Roche
  • Bristol Myers Squibb
  • Merck
  • GlaxoSmithKline
  • Johnson & Johnson
  • Amgen
  • Novartis
  • AstraZeneca
  • Eli Lilly
  • AbbVie

Cancer Monoclonal Antibodies Market Insights

Lucintel forecasts that humanized is expected to witness the highest growth over the forecast period due to affordability, availability, and lesser production time for mouse monoclonal antibodies.

Within this market, hospitals will remain the largest segment due increasing prevalence of cancer along with growing number of patient hospitalizations.

North America will remain the largest region over the forecast period due to growing awarness towards advanced therapies, rising prevalence of cancer, and presence of major market players in the region.

Features of the Global Cancer Monoclonal Antibodies Market

Market Size Estimates: Cancer monoclonal antibodies market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Cancer monoclonal antibodies market size by type, application, end use, and region in terms of value ($B).

Regional Analysis: Cancer monoclonal antibodies market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, end uses, and regions for the cancer monoclonal antibodies market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer monoclonal antibodies market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the cancer monoclonal antibodies market size?

Answer: The global cancer monoclonal antibodies market is expected to reach an estimated $153.7 billion by 2030.

Q2. What is the growth forecast for cancer monoclonal antibodies market?

Answer: The global cancer monoclonal antibodies market is expected to grow with a CAGR of 12.4% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the cancer monoclonal antibodies market?

Answer: The major drivers for this market are increasing investment in research and development activities, rising inclination towards personalized medicines, and growing prevalance of cancer across the globe.

Q4. What are the major segments for cancer monoclonal antibodies market?

Answer: The future of the cancer monoclonal antibodies market looks promising with opportunities in the hospital and research institute markets.

Q5. Who are the key cancer monoclonal antibodies market companies?

Answer: Some of the key cancer monoclonal antibodies companies are as follows:

  • F. Hoffmann-La Roche
  • Bristol Myers Squibb
  • Merck
  • GlaxoSmithKline
  • Johnson & Johnson
  • Amgen
  • Novartis
  • AstraZeneca
  • Eli Lilly
  • AbbVie

Q6. Which cancer monoclonal antibodies market segment will be the largest in future?

Answer: Lucintel forecasts that humanized is expected to witness the highest growth over the forecast period due to affordability, availability, and lesser production time for mouse monoclonal antibodies.

Q7. In cancer monoclonal antibodies market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing awarness towards advanced therapies, rising prevalence of cancer, and presence of major market players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the cancer monoclonal antibodies market by type (humanized, human, chimeric, and murine), application (blood cancer, breast cancer, lung cancer, melanoma, colorectal cancer, liver cancer, and others), end use (hospitals, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Cancer Monoclonal Antibodies Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Cancer Monoclonal Antibodies Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Cancer Monoclonal Antibodies Market by Type
    • 3.3.1: Humanized
    • 3.3.2: Human
    • 3.3.3: Chimeric
    • 3.3.4: Murine
  • 3.4: Global Cancer Monoclonal Antibodies Market by Application
    • 3.4.1: Blood Cancer
    • 3.4.2: Breast Cancer
    • 3.4.3: Lung Cancer
    • 3.4.4: Melanoma
    • 3.4.5: Colorectal Cancer
    • 3.4.6: Liver Cancer
    • 3.4.7: Others
  • 3.5: Global Cancer Monoclonal Antibodies Market by End Use
    • 3.5.1: Hospitals
    • 3.5.2: Research Institutes
    • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Cancer Monoclonal Antibodies Market by Region
  • 4.2: North American Cancer Monoclonal Antibodies Market
    • 4.2.2: North American Cancer Monoclonal Antibodies Market by End Use: Hospitals, Research Institutes, and Others
  • 4.3: European Cancer Monoclonal Antibodies Market
    • 4.3.1: European Cancer Monoclonal Antibodies Market by Type: Humanized, Human, Chimeric, and Murine
    • 4.3.2: European Cancer Monoclonal Antibodies Market by End Use: Hospitals, Research Institutes, and Others
  • 4.4: APAC Cancer Monoclonal Antibodies Market
    • 4.4.1: APAC Cancer Monoclonal Antibodies Market by Type: Humanized, Human, Chimeric, and Murine
    • 4.4.2: APAC Cancer Monoclonal Antibodies Market by End Use: Hospitals, Research Institutes, and Others
  • 4.5: ROW Cancer Monoclonal Antibodies Market
    • 4.5.1: ROW Cancer Monoclonal Antibodies Market by Type: Humanized, Human, Chimeric, and Murine
    • 4.5.2: ROW Cancer Monoclonal Antibodies Market by End Use: Hospitals, Research Institutes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Cancer Monoclonal Antibodies Market by Type
    • 6.1.2: Growth Opportunities for the Global Cancer Monoclonal Antibodies Market by Application
    • 6.1.3: Growth Opportunities for the Global Cancer Monoclonal Antibodies Market by End Use
    • 6.1.4: Growth Opportunities for the Global Cancer Monoclonal Antibodies Market by Region
  • 6.2: Emerging Trends in the Global Cancer Monoclonal Antibodies Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Cancer Monoclonal Antibodies Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Monoclonal Antibodies Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: F. Hoffmann-La Roche
  • 7.2: Bristol Myers Squibb
  • 7.3: Merck
  • 7.4: GlaxoSmithKline
  • 7.5: Johnson & Johnson
  • 7.6: Amgen
  • 7.7: Novartis
  • 7.8: AstraZeneca
  • 7.9: Eli Lilly
  • 7.10: AbbVie